Insulet
PODD
#1310
Rank
$16.68 B
Marketcap
$237.01
Share price
-1.63%
Change (1 day)
-0.02%
Change (1 year)
Categories
Insulet Corporation is an American company that develops and sells medical devices used for the administration of insulin.

P/E ratio for Insulet (PODD)

P/E ratio as of March 2026 (TTM): 67.7

According to Insulet's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 67.7171. At the end of 2024 the company had a P/E ratio of 43.7.

P/E ratio history for Insulet from 2007 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202443.7-40.64%
202373.6-98.25%
2022> 1000263.54%
2021> 1000-50.22%
2020> 1000144.34%
2019951-28.06%
2018> 1000-981.33%
2017-150103.03%
2016-73.9152.07%
2015-29.3-40.82%
2014-49.510.8%
2013-44.7127.5%
2012-19.628.34%
2011-15.3

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
21.6-68.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
29.2-56.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Medtronic
MDT
24.5-63.82%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
Eli Lilly
LLY
43.0-36.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Tandem Diabetes Care
TNDM
-6.93-110.24%๐Ÿ‡บ๐Ÿ‡ธ USA
ICU Medical
ICUI
-426-728.80%๐Ÿ‡บ๐Ÿ‡ธ USA
DexCom
DXCM
36.8-45.64%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.